How do different drug classes work in treating Type 1 diabetes?

Overview of Type 1 Diabetes

Type 1 diabetes (T1D) is fundamentally an autoimmune disease in which the body's immune system erroneously targets and destroys pancreatic β‐cells, the specialized cells that produce and secrete insulin. Without sufficient β‐cells, endogenous insulin production sharply declines (often to 10–15% of normal levels), leading to absolute insulin deficiency and high blood glucose levels (hyperglycemia). This chronic condition is characterized by a complex interplay of genetic predisposition and environmental triggers that culminate in chronic inflammation (insulitis), which further accelerates the destruction of β‐cells. The loss of β‐cell mass not only mandates an exogenous replacement of insulin throughout life but also initiates a cascade of metabolic disturbances. These include dysregulated glucagon secretion by the pancreatic α‐cells, increased hepatic glucose production, and eventual development of both microvascular (e.g., retinopathy, neuropathy, nephropathy) and macrovascular complications such as cardiovascular disease. Furthermore, secondary complications such as insulin resistance—once considered exclusive to type 2 diabetes—are increasingly recognized even in T1D, particularly in overweight patients or those with prolonged disease duration. Overall, the pathophysiologic mechanisms of T1D form the basis for targeted pharmacological interventions and inform the rationale for insulin replacement therapy, as well as the use of adjunctive therapies.

Current Treatment Landscape 
The mainstay of T1D management continues to be intensive insulin therapy. Since the discovery of insulin in the early 1920s, its role as a life-saving treatment has been unchallenged; however, modern-day management now incorporates advanced insulin delivery systems, continuous glucose monitoring (CGM), and automated dosing guidance to help maintain glycemic control and reduce the risk of complications. Despite these advancements, many patients still struggle to achieve target glycated hemoglobin (HbA1c) levels due to the fine balance required between insulin dosages, endogenous control, and the risk of hypoglycemia. Accordingly, the evolving treatment paradigm now recognizes the potential benefits of adjunctive therapies beyond traditional insulin. Non‐insulin agents—already extensively used for type 2 diabetes—are being repurposed and studied for T1D for their abilities to address insulin resistance, reduce insulin requirements, ameliorate postprandial glucose excursions, and offer cardiovascular and renal benefits. Thus, the current treatment landscape for T1D is characterized by a combination of insulin‐based therapy, advanced technological approaches, and emerging adjunctive therapies designed to optimize glycemic control while minimizing adverse metabolic consequences.

Drug Classes for Type 1 Diabetes Treatment

Insulin Therapy 
Insulin remains the cornerstone of T1D management. The primary rationale for its use is that the absolute deficiency of endogenous insulin, resulting from autoimmune β‐cell destruction, necessitates exogenous replacement. Insulin therapy essentially works by mimicking the physiological secretory pattern of insulin, which includes both basal and prandial components. Basal insulin is intended to provide a continuous low level of insulin to maintain fasting and between-meal glucose control, whereas bolus or prandial insulin addresses the rises in blood glucose following meals. 
There is an array of insulin formulations available:

• Human Insulin and Regular Insulin: Early treatments involved human insulin preparations; however, these often exhibited pharmacokinetic profiles that did not optimally mimic the physiological insulin secretion, leading to issues such as postprandial hyperglycemia or hypoglycemia due to unpredictable absorption rates. 
• Rapid-Acting Insulin Analogs: These are engineered to have a quick onset, peak at approximately an hour post-injection, and then subside relatively quickly. Their design allows them to address glucose rises in the postprandial period more effectively and with lower risk of post-meal hypoglycemia. 
• Long-Acting Insulin Analogs: Such as insulin glargine, detemir, and degludec are modified to provide a “peakless” basal profile with prolonged durations of action (up to 24 hours or more). They are designed to reduce the variability of insulin absorption and thereby lower the risk of hypoglycemia, particularly nocturnal episodes. 
• Combination/Co-formulations: Recent advances have led to fixed-ratio or co-formulated insulins that combine basal and rapid-acting components to simplify regimens and improve glycemic control. These formulations aim to reduce the treatment burden while maintaining efficacy.

Thus, insulin therapy in T1D works by replacing the deficient hormone, acting via insulin receptor activation on peripheral tissues, stimulating glucose uptake (especially in muscle and adipose tissue), and inhibiting hepatic gluconeogenesis. This method restores metabolic homeostasis in the short term but does not address the underlying autoimmune process, hence the need for continued reliance on exogenous insulin.

Adjunctive Therapies 
While insulin is essential, monotherapy with insulin does not fully address the multifaceted metabolic derangements seen in T1D. Adjunctive therapies are increasingly being explored and, in some cases, adopted to enhance glycemic control, reduce insulin dosages, and potentially ameliorate long-term complications. 
There are several adjunctive drug classes being considered for T1D treatment:

• SGLT2 Inhibitors: Originally developed for type 2 diabetes, sodium-glucose cotransporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys, thereby increasing urinary glucose excretion. In T1D, these agents have been studied as add-on therapies to insulin, showing improvements in HbA1c levels, reduction in body weight, and even lowering of total daily insulin doses while maintaining a low hypoglycemia risk. However, they are associated with an increased risk of diabetic ketoacidosis (DKA), which mandates careful patient selection and monitoring. 
• GLP-1 Receptor Agonists: These agents mimic the action of the incretin hormone glucagon-like peptide 1 (GLP-1) by stimulating insulin secretion in a glucose-dependent manner and suppressing glucagon release. Although primarily used for type 2 diabetes, they have been investigated in T1D as adjuncts to insulin therapy. Clinical studies indicate that they can facilitate weight loss, modest reductions in HbA1c, and a decrease in total daily insulin requirements. Their use, though off-label in many settings for T1D, represents a promising avenue for improving overall metabolic control. 
• Other Emerging Therapies: Researchers are also exploring immune-modulating drugs, β-cell regenerative agents (such as GABA and certain epigenetic modifiers), and agents targeting the inflammatory cascade. These therapies aim to either curb the autoimmune destruction of β-cells or promote the regeneration of residual β-cell mass, thus potentially altering the disease course. Recent studies using epigenetic drugs (for example, I-BET151) have shown promise in animal models by dampening local inflammation while promoting β-cell proliferation.

Adjunctive therapies work by leveraging alternative mechanisms of action that complement insulin replacement. They help improve glycemic control by reducing glucose variability, decreasing oxidative stress and inflammation, and in some cases, offering cardiovascular and renal protection. The ultimate goal is to optimize the management of T1D beyond what is achievable with insulin therapy alone, thereby mitigating complications related to poor glycemic control and excessive insulin dosage.

Mechanisms of Action

Insulin and Its Variants 
The central mechanism of insulin involves its binding to the insulin receptor (IR) on target cells. Once bound, insulin undergoes receptor-mediated endocytosis and triggers a cascade of intracellular signaling events. Key pathways include the phosphatidylinositol-3-kinase (PI3K)/Akt pathway, which promotes glucose uptake primarily via translocation of GLUT-4 transporters to the cell surface in muscle and adipose tissue, and the MAPK pathway which is involved in cell growth and gene expression regulation. 
Different insulin analogs have been engineered to modify the duration and onset of action:

• Rapid-Acting Analogs (e.g., lispro, aspart, glulisine): These are modified structurally to reduce the formation of hexamers at the injection site, thereby enabling a faster absorption into the bloodstream. They begin acting within minutes and peak around one hour post-injection, mimicking the natural first-phase insulin response to food intake. The molecular modifications also help maintain similar receptor binding characteristics to native insulin, though slight differences in the intracellular signaling kinetics may occur. 
• Long-Acting Analogs (e.g., glargine, detemir, degludec): These analogs have alterations that prolong their duration of action. For instance, insulin glargine is formulated at a slightly acidic pH, which upon injection precipitates into microcrystals that slowly dissolve over time. Insulin detemir is altered to bind reversibly to albumin in the bloodstream, thereby extending its activity. These formulations are designed to offer a relatively constant level of insulin, aiming to mimic basal insulin secretion with minimal peaks, thus reducing the risk of hypoglycemia. 
• Biosynthetic and Hybrid Insulins: Research has also focused on combining molecular design and genetic engineering approaches to create novel insulin molecules that offer improved pharmacokinetics and pharmacodynamics, potentially with reduced side effects such as mitogenic risk or amyloid formation. 

In summary, insulin and its variants function by directly replacing the absent or insufficient insulin in T1D. Their use is tailored to meet both the rapid increases in blood glucose following meals (rapid-acting) as well as to maintain a stable baseline level (long-acting), ensuring effective metabolic control.

SGLT2 Inhibitors 
SGLT2 inhibitors target a completely different aspect of the glucose regulation system. Sodium-glucose cotransporter 2 (SGLT2) is a protein localized in the early segments of the renal proximal tubule. Its primary role is the reabsorption of approximately 90% of the filtered glucose from the glomerular filtrate back into circulation. 
By inhibiting SGLT2, these drugs reduce renal glucose reabsorption, thereby increasing urinary glucose excretion—a process known as glycosuria. The resulting loss of glucose from the body not only lowers blood glucose levels but also contributes to a caloric deficit, which can result in weight loss. Importantly, because the mechanism is independent of insulin secretion or sensitivity, SGLT2 inhibitors have a low inherent risk of hypoglycemia. 
In T1D, their adjunctive use has demonstrated benefits such as reductions in HbA1c, decreased fasting and postprandial plasma glucose levels, and reduced total daily insulin requirements. However, a critical concern with SGLT2 inhibitors is the risk of diabetic ketoacidosis (DKA), especially in patients with T1D. The mechanism behind increased DKA risk appears to be related to the reduced insulin dosage in the setting of persistent counter-regulatory hormone activity, which may promote lipolysis and ketogenesis. Therefore, although SGLT2 inhibitors offer significant metabolic benefits—including improvements in blood pressure and potential cardiovascular and renal protection—they require careful patient selection and vigilant monitoring to prevent adverse outcomes such as DKA.

GLP-1 Receptor Agonists 
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) represent another class of adjunctive therapies originally developed for type 2 diabetes but now investigated in T1D. These agents act as mimetics of the endogenous incretin hormone GLP-1, which is produced in the intestine in response to food intake. The natural hormone GLP-1 stimulates insulin secretion in a glucose-dependent manner, inhibits glucagon secretion, slows gastric emptying, and increases satiety—factors that collectively contribute to improved postprandial glycemic control. 
GLP-1 RAs are engineered to have longer half-lives than endogenous GLP-1, which is rapidly degraded by dipeptidyl peptidase-4 (DPP-4). By resisting degradation, these agonists maintain sustained receptor stimulation. In the context of T1D, although endogenous insulin secretion is severely compromised, GLP-1 RAs can still play a role by suppressing inappropriate glucagon secretion from α-cells, thereby reducing hepatic glucose production. This dual action not only aids in lowering blood glucose levels but may also reduce the amount of insulin required, mitigating issues such as weight gain associated with high insulin doses. Additionally, some studies have shown that GLP-1 RAs might confer cardiovascular benefits through improvements in blood pressure, lipid profiles, and inflammatory markers. 
Thus, the mechanism of action of GLP-1 RAs in T1D involves leveraging the incretin pathway to provide a more refined control of postprandial glucose levels and glucagon suppression while contributing to weight control and potentially offering cardiovascular protection.

Comparative Efficacy and Safety

Clinical Trial Outcomes 
A substantial body of clinical research has evaluated the efficacy of different drug classes in the management of T1D. 
• Insulin Therapy: Clinical trials have historically demonstrated that intensive insulin therapy can significantly reduce HbA1c levels, thereby lowering the risk of microvascular complications. With the advent of rapid- and long-acting insulin analogs, outcomes have improved with more physiologic insulin substitution patterns and reduced variability in glycemic control. The evolution from conventional human insulin to analogs has resulted in fewer hypoglycemic events and improved patient adherence, as supported by multiple randomized controlled trials and retrospective studies. 
• SGLT2 Inhibitors: Recent clinical investigations into the use of SGLT2 inhibitors as adjunctive therapy in T1D have shown promising results. Meta-analyses of several randomized trials indicate that these agents reduce fasting plasma glucose by approximately 0.69 mmol/L, lower HbA1c by around 0.37%, and contribute to weight losses of approximately 2.5 kg, while also reducing the overall insulin dose by about 6 units per day. However, despite these metabolic benefits, an increased incidence of diabetic ketoacidosis (DKA) in some studies has raised concerns regarding long-term safety and appropriate patient selection. 
• GLP-1 Receptor Agonists: Clinical trials of GLP-1 RAs as an adjunct to insulin in T1D have demonstrated modest improvements in glycemic control, significant weight loss, and reductions in total daily insulin requirements. Although the magnitude of HbA1c reduction is not as pronounced as with insulin or SGLT2 inhibitors, the additional benefits of weight loss and potentially improved cardiovascular risk profiles make them attractive candidates for personalized treatment regimens. Studies consistently show that GLP-1 RAs reduce postprandial glucose excursions and suppress glucagon secretion, thereby complementing insulin therapy.

Each of these clinical outcomes is measured not only by classical glycemic indicators such as HbA1c, fasting, and postprandial blood glucose levels but also by assessments of weight, insulin dose requirements, and, importantly, cardiovascular risk markers. The cross-sectional and longitudinal data present in the literature indicate that while insulin therapy remains non-negotiable in T1D, the adjunctive use of SGLT2 inhibitors and GLP-1 receptor agonists adds value by targeting distinct pathophysiological pathways.

Side Effects and Management 
While the efficacy of each drug class in treating T1D is encouraging, a comprehensive understanding of the safety profiles is critical for effective management: 
• Insulin Therapy: Although insulin is life-saving, its major side effects include hypoglycemia and weight gain. Innovations in insulin analogs have partly mitigated these risks by providing more predictable action profiles. Nevertheless, the risk of hypoglycemia remains a persistent clinical challenge, especially with intensive insulin regimens. Modern insulin pumps and continuous glucose monitors have been developed to aid in minimizing these risks by providing real-time blood glucose feedback and automated adjustments in insulin delivery. 
• SGLT2 Inhibitors: The most significant safety concern with SGLT2 inhibitors in T1D is the risk of developing diabetic ketoacidosis (DKA), even when blood glucose levels are not markedly elevated (euglycemic DKA). Other potential adverse events include urinary tract infections and genital mycotic infections due to the glycosuric effect of these drugs. Because of these concerns, patient education is paramount, including instruction on ketone monitoring, awareness of DKA symptoms, and guidance on insulin dose adjustments when initiating SGLT2 inhibitor therapy. 
• GLP-1 Receptor Agonists: The primary adverse effects associated with GLP-1 RAs are gastrointestinal in nature, including nausea, vomiting, and diarrhea. These side effects are generally transient and diminish over time as patients acclimatize to the medication. Furthermore, there have been concerns over potential risks related to pancreatitis and, although data remain inconclusive, ongoing long-term studies are addressing these issues. Importantly, the risk of hypoglycemia with GLP-1 RAs is low when used alone or as an adjunct to insulin, making them a safer option for improving postprandial glycemic control and reducing insulin dosage.

The management of these side effects revolves around careful patient selection, dose titration, and continuous monitoring. For instance, patients who are prone to DKA are advised to use SGLT2 inhibitors with extreme caution, while those experiencing intolerable gastrointestinal side effects with GLP-1 RAs may benefit from gradual dose escalation or switching to alternative formulations that are better tolerated.

Future Directions in Type 1 Diabetes Treatment

Emerging Therapies 
Looking ahead, the future of T1D treatment appears to be focused on expanding therapeutic options that address not only glycemic control but also the underlying autoimmune process and complications associated with chronic hyperglycemia. Emerging therapies include: 

• Immunomodulatory and β-Cell Preservation Agents: There is growing interest in interventions that can modulate the immune system to preserve remaining β-cell function or to delay further β-cell destruction. Agents that target the autoimmune process, such as anti-CD3 antibodies, autoantigen-based therapies, and newer immunomodulators, are under investigation to slow disease progression. For example, while trials involving autoantigen-specific immunotherapy have shown mixed results, they hold promise in preserving endogenous insulin secretion during the early “honeymoon” phase of T1D. 

• β-Cell Regenerative Therapies: Research is also exploring the potential of agents that stimulate β-cell regeneration. Molecules such as GABA and certain epigenetic drugs like I-BET151 have shown in preclinical models the capability to promote β-cell proliferation or facilitate transdifferentiation from α-cells to β-cells. This approach aims at restoring the lost endocrine function of the pancreas, thereby reducing or even potentially eliminating the need for exogenous insulin over time.

• Combination Therapies: The next frontier in T1D management is likely to involve the rational combination of different drug classes to target multiple pathways simultaneously. For instance, combining insulin with an SGLT2 inhibitor may not only improve glycemic control but also reduce insulin doses and weight gain, while adding a GLP-1 receptor agonist could further suppress inappropriate glucagon secretion and enhance postprandial glucose control. Such combination therapies will need to be optimized based on patient-specific characteristics such as age, disease duration, body mass index (BMI), and presence of comorbidities.

• Advanced Drug Delivery Technologies: The evolution of insulin management is closely intertwined with advancements in drug delivery and monitoring technology. Innovations such as closed-loop insulin delivery systems (artificial pancreas) and smart insulin pens integrated with continuous glucose monitoring are revolutionizing diabetes care by providing real-time adjustments and reducing treatment burden. Future developments may see similar technologies being applied to the administration of adjunctive therapies, ensuring that the dosing of insulin and non-insulin agents is optimally synchronized with the patient’s metabolic needs.

These emerging strategies reflect a move toward more personalized medicine in diabetes care, where large-scale clinical trials are increasingly complemented by real-world evidence and molecular data, allowing clinicians to tailor therapy based on individual patient profiles.

Research and Development Trends 
Several trends are shaping the future of T1D treatment research: 

• Translational Research Efforts: The integration of basic science insights with clinical investigations is leading to a better understanding of the molecular mechanisms underpinning T1D. Studies focusing on the roles of inflammation, immune dysregulation, and metabolic stress are uncovering novel targets for drug development. Continued research in this area is vital to develop agents that can modify the disease course rather than merely controlling its symptoms. 

• Personalized Medicine and Biomarkers: The identification of specific biomarkers linked to disease progression, treatment response, and complication risk is pivotal for the development of personalized treatment strategies. Ongoing research involving genomic, proteomic, and metabolomic approaches aims to identify patients who may benefit most from adjunctive therapies such as SGLT2 inhibitors or GLP-1 RAs. In the future, such biomarkers may assist in tailoring combination therapy regimens that maximize efficacy while minimizing adverse effects. 

• Combination Regimens and Clinical Algorithms: There is increasing interest in constructing clinical algorithms that incorporate multiple drug classes. These algorithms will help clinicians decide on the optimal combination and sequencing of therapies based on individual characteristics and responses. Recent studies have shown that systematic rotation through different drug classes (for example, the use of various UACR-lowering drugs) can overcome therapy resistance and improve clinical outcomes. Similar strategies may be applied to the combined use of insulin with SGLT2 inhibitors and GLP-1 RAs in T1D management.

• Safety and Long-Term Outcome Studies: Despite the encouraging benefits seen with adjunctive therapies, long-term safety data, especially for off-label uses in T1D, remain limited. Future research efforts will need to focus on understanding rare adverse events, such as the risk of DKA with SGLT2 inhibitors or any potential pancreatic or thyroid issues with GLP-1 RAs, through large multi-center, longitudinal studies. 

• Health Economic Evaluations: Cost-effectiveness analyses and real-world studies are becoming increasingly critical in determining the adoption of new therapies. As newer agents potentially reduce the burden of diabetes-related complications and improve quality of life, comprehensive economic evaluations are essential to justify their use in broader populations and guide healthcare reimbursement policies.

Conclusion 
In conclusion, the pharmacological treatment of Type 1 diabetes is evolving from a sole reliance on exogenous insulin replacement toward a multi-dimensional approach that incorporates both insulin therapy and adjunctive agents. Insulin therapies—including rapid-acting and long-acting analogs—fundamentally work by mimicking the endogenous insulin profile and activating receptor-mediated pathways to promote glucose uptake and inhibit hepatic glucose production. In parallel, adjunctive therapies such as SGLT2 inhibitors and GLP-1 receptor agonists target complementary pathways. SGLT2 inhibitors reduce blood glucose levels by promoting glucosuria and are associated with weight loss and reduced insulin requirements; however, the risk of DKA necessitates careful clinical vigilance. Meanwhile, GLP-1 receptor agonists leverage the incretin effect to stimulate insulin secretion in a glucose-dependent manner and suppress glucagon release, contributing to improved postprandial glucose control, reduced insulin dosage, weight loss, and potential cardiovascular protection.

Comparative analyses of clinical trial outcomes indicate that while intensive insulin therapy remains indispensable for T1D management, the adjunctive use of SGLT2 inhibitors and GLP-1 receptor agonists can significantly optimize metabolic control, reduce complication risk, and improve patient quality of life. Yet, they also come with unique safety challenges—including hypoglycemia with insulin, and risks such as DKA and gastrointestinal side effects with SGLT2 inhibitors and GLP-1 RAs, respectively—that require careful management and patient education.

Looking ahead, future directions in T1D treatment are marked by emerging therapies aimed at preserving or regenerating β-cell mass, the development of combination regimens that address multiple pathogenic mechanisms simultaneously, and the incorporation of advanced technology to personalize and automate therapy. Simultaneously, translational research is geared toward understanding the immunologic and molecular underpinnings of the disease further, with a view to developing interventions that modify the disease course rather than merely treating its symptoms. Ongoing real-world studies and long-term clinical trials will be essential to evaluate the safety, cost-effectiveness, and efficacy of these novel therapeutic approaches in diverse patient populations.

Overall, addressing T1D requires a general-specific-general approach: beginning with a broad understanding of the autoimmune destruction and metabolic dysregulation underlying the disease, delving deep into the specific mechanisms by which traditional and emerging drugs exert their effects, and finally integrating these insights to optimize and personalize treatment strategies that not only control blood glucose but also reduce the risk of long-term complications. The integration of diverse drug classes represents an exciting frontier in T1D management—one that holds the promise of not only improving glycemic outcomes but also enhancing overall patient well-being and quality of life.

Ultimately, the future of T1D treatment is likely to be characterized by a tailored, multidisciplinary regimen that strategically combines insulin with adjunctive therapies, leverages ongoing technological advancements, and continuously evolves with the growing understanding of the disease’s complex pathophysiology. Continued research and robust clinical trials will play a vital role in refining these therapies, ensuring that patients receive the optimal balance of efficacy and safety as we push forward into an era of personalized diabetes care.

Discover Eureka LS: AI Agents Built for Biopharma Efficiency

Stop wasting time on biopharma busywork. Meet Eureka LS - your AI agent squad for drug discovery.

▶ See how 50+ research teams saved 300+ hours/month

From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.